Zeta PD-1 Antibody. Zeta’s rabbit recombinant monoclonal antibody recognizes PD-1 (PDCD1). PD-1 (PDCD-1 programmed cell death-1 protein), designated CD279, is a type I transmembrane receptor and a member of the immunoglobin gene superfamily. PD-1 (PDCD1) is expressed on activated T-cells, B-cells, and myeloid cells. Zeta’s antibody to PD-1 (PDCD-1) is a marker of angioimmunoblastic lymphoma and suggests a unique cell of origin for this neoplasm. Unlike CD10 and BCL6, PD-1 (PDCD-1) is expressed by few B-cells, so the antibody to PD-1 (PDCD-1) may be a more specific and valuable diagnostic marker in angioimmunoblastic lymphoma. In addition, PD-1 (PDCD-1) expression provides evidence that angioimmunoblastic lymphoma is a neoplasm derived from germinal center-associated T-cells.
Immunotherapy, based on immune checkpoint inhibitors (ICIs) targeting the programmed cell death ligand 1 (PD-L1) and/or programmed death receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. However, only ~30% of patients benefit from ICIs.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.